Hypnotics and Triazolobenzodiazepines - Best Predictors of High-Dose Benzodiazepine Use: Results from the Luxembourg National Health Insurance Registry

Psychotherapy and Psychosomatics

Volumn 84, Issue 5, 2015, Pages 273-283

  Cloos, Jean Marc ^a,b   Bocquet, Valéry ^c   Rolland Portal, Isabelle ^d   Koch, Paul ^d   Chouinard, Guy ^e,f,g,h  

^a Hôpitaux Robert Schuman Zithaklinik   (Luxembourg)

^b Jugend an Drogenhëllef   (Luxembourg)

^c LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^d Inspection Générale de la Sécurité Sociale   (Luxembourg)

^e ZithaKlinik   (Luxembourg)

^f MCGILL UNIVERSITY   (Canada)

^g CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^h Sorbonne Paris Cité University Group   (France)

Author keywords

Anxiolytics; Benzodiazepine high dose use; Benzodiazepine long term use; Benzodiazepine prevalence; Hypnotics

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; BROTIZOLAM; CLOBAZAM; CLONAZEPAM; CLORAZEPATE; CLOTIAZEPAM; CLOXAZOLAM; DIAZEPAM; FLUNITRAZEPAM; FLURAZEPAM; KETAZOLAM; LOFLAZEPATE; LOPRAZOLAM; LORAZEPAM; LORMETAZEPAM; MIDAZOLAM; NITRAZEPAM; NORDAZEPAM; OXAZEPAM; PRAZEPAM; TEMAZEPAM; TETRAZEPAM; TRIAZOLAM; ANXIOLYTIC AGENT; HYPNOTIC SEDATIVE AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; DRUG USE; DRUG UTILIZATION; FEMALE; HUMAN; LUXEMBOURG; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH INSURANCE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; DRUG TOLERANCE; MIDDLE AGED; REGISTER; RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-ANXIETY AGENTS; BENZODIAZEPINES; DRUG TOLERANCE; DRUG UTILIZATION; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES;

EID: 84939530886     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000434755     Document Type: Article

References (53)

1. Rosenbaum JF: The drug treatment of anxiety. N Engl J Med 1982; 306: 401-404.
2. Shader RI, Greenblatt DJ: Use of benzodiazepines in anxiety disorders. N Engl J Med 1993; 328: 1398-1405.
3. Smith MT, Perlis ML, Park A, Smith MS, Pennington J, Giles DE, Buysse DJ: Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry 2002; 159: 5-11.
4. Offidani E, Guidi J, Tomba E, Fava GA: Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis. Psychother Psychosom 2013; 82: 355-362.
5. Chouinard G: Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry 2004; 65(suppl 5):7-12.
6. Silber MH: Clinical practice. Chronic insomnia. N Engl J Med 2005; 353: 803-810.
7. Fava GA: Rational use of antidepressant drugs. Psychother Psychosom 2014; 83: 197-204.
8. Rickels K: Should benzodiazepines be replaced by antidepressants in the treatment of anxiety disorders? Fact or fiction? Psychother Psychosom 2013; 82: 351-352.
9. Balon R: Benzodiazepines revisited. Psychother Psychosom 2013; 82: 353-354.
10. Chouinard G, Chouinard VA: New classification of selective serotonin reuptake inhibitor withdrawal. Psychother Psychosom 2015; 84: 63-71.
11. Fava GA, Gatti A, Belaise C, Guidi J, Offidani E: Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom 2015; 84: 72-81.
12. Fava GA, Balon R, Rickels K: Benzodiazepines in anxiety disorders. JAMA Psychiatry 2015;72:733-734.
13. Zandstra SM, Furer JW, van de Lisdonk EH, van't Hof M, Bor JH, van Weel C, Zitman FG: Different study criteria affect the prevalence of benzodiazepine use. Soc Psychiatry Psychiatr Epidemiol 2002; 37: 139-144.
14. Furtado C, Teixeira I: Utilizacao de benzodiazepinas em Portugal continental (1999-2003). Acta Med Port 2006; 19: 239-246.
15. Sonnenberg CM, Bierman EJ, Deeg DJ, Comijs HC, van Tilburg W, Beekman AT: Tenyear trends in benzodiazepine use in the Dutch population. Soc Psychiatry Psychiatr Epidemiol 2012; 47: 293-301.
16. Holm E, Fosbol E, Pedersen H, Jensen TB, Nielsen M, Weeke P, Brinth L, Torp-Pedersen C: Benzodiazepine use in Denmark 1997-2008. Eur Geriatr Med 2012; 3: 299-303.
17. Vicente Sanchez MP, Macias Saint-Gerons D, de la Fuente Honrubia C, Gonzalez Bermejo D, Montero Corominas D, Catala-Lopez F: Evolucion del uso de medicamentos ansioliticos e hipnoticos en Espana durante el periodo 2000-2011. Rev Esp Salud Publica 2013; 87: 247-255.
18. Olfson M, King M, Schoenbaum M: Benzodiazepine use in the United States. JAMA Psychiatry 2015; 72: 136-142.
19. Zandstra SM, Furer JW, van de Lisdonk EH, Bor JH, Zitman FG, van Weel C: Differences in health status between long-term and shortterm benzodiazepine users. Br J Gen Pract 2002; 52: 805-808.
20. Liang KY, Zeger SL: Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 13-22.
21. Cui J, Qian G: Selection of working correlation structure and best model in GEE analyses of longitudinal data. Commun Stat-Simul C 2007; 36: 987-996.
22. World Health Organization: Guidelines for ATC Classification and DDD Assignment. Oslo, WHO Collaborating Centre for Drug Statistics Methodology, 2012.
23. Soumerai SB, Simoni-Wastila L, Singer C, Mah C, Gao X, Salzman C, Ross-Degnan D: Lack of relationship between long-term use of benzodiazepines and escalation to high dosages. Psychiatr Serv 2003; 54: 1006-1011.
24. Martinez-Cano H, Vela-Bueno A, De Iceta M, Pomalima R, Martinez-Gras I, Sobrino MP: Benzodiazepine types in high versus therapeutic dose dependence. Addiction 1996; 91: 1179-1186.
25. Neutel CI: The epidemiology of long-term benzodiazepine use. Int Rev Psychiatry 2005; 17: 189-197.
26. Shorr RI, Robin DW: Rational use of benzodiazepines in the elderly. Drugs Aging 1994; 4: 9-20.
27. Madhusoodanan S, Bogunovic OJ: Safety of benzodiazepines in the geriatric population. Expert Opin Drug Saf 2004; 3: 485-493.
28. Schweizer E, Case WG, Rickels K: Benzodiazepine dependence and withdrawal in elderly patients. Am J Psychiatry 1989; 146: 529-531.
29. Tvete IF, Bjorner T, Aursnes IA, Skomedal T: A 3-year survey quantifying the risk of dose escalation of benzodiazepines and congeners to identify risk factors to aid doctors to more rational prescribing. BMJ Open 2013; 3:e003296.
30. Memorial A: reglement grand-ducal du 14 janvier 2000 modifiant l'annexe du reglement grand-ducal modifie du 4 mars 1974 concernant certaines substances toxiques. Journal Officiel du Grand-Duche de Luxembourg 2000; 5: 165.
31. Buysse DJ: Insomnia. JAMA 2013; 309: 706-716.
32. Cavalie P, Richard N: Rapport d'expertise: etat des lieux de la consommation des benzodiazepines en France. Saint-Denis, Agence francaise de securite sanitaire des produits de sante, 2012.
33. Beuscart JB, Dupont C, Defebvre MM, Puisieux F: Potentially inappropriate medications (PIMs) and anticholinergic levels in the elderly: a population based study in a French region. Arch Gerontol Geriatr 2014; 59: 630-635.
34. Gruppo di lavoro OsMed: L'uso dei farmaci in Italia: rapporto nazionale anno 2011. Rome, Il Pensiero Scientifico, 2012.
35. Magrini N, Vaccheri A, Parma E, D'Alessandro R, Bottoni A, Occhionero M, Montanaro N: Use of benzodiazepines in the Italian general population: prevalence, pattern of use and risk factors for use. Eur J Clin Pharmacol 1996; 50: 19-25.
36. Ciuna A, Andretta M, Corbari L, Levi D, Mirandola M, Sorio A, Barbui C: Are we going to increase the use of antidepressants up to that of benzodiazepines? Eur J Clin Pharmacol 2004; 60: 629-634.
37. Petitjean S, Ladewig D, Meier CR, Amrein R, Wiesbeck GA: Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies. Int Clin Psychopharmacol 2007; 22: 292-298.
38. Sakshaug S: Drug Consumption in Norway 2007-2011 (Legemiddelforbruket i Norge 2007-2011). Oslo, Norwegian Institute of Public Health, 2012.
39. Gualano MR, Bert F, Mannocci A, La Torre G, Zeppegno P, Siliquini R: Consumption of antidepressants in Italy: recent trends and their significance for public health. Psychiatr Serv 2014; 65: 1226-1231.
40. Olkkola KT, Ahonen J: Midazolam and other benzodiazepines; in Schuttler J, Schwilden H (eds): Handbook of Experimental Pharmacology. Heidelberg, Springer, 2008, vol 182: Modern Anesthetics, pp 335-360.
41. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther 2002; 300: 2-8.
42. Te Beek ET, Chen X, Jacobs GE, Nahon KJ, de Kam ML, Lappalainen J, Cross AJ, van Gerven JMA, Hay JL: The effects of the nonselective benzodiazepine lorazepam and the ? 2 /? 3 subunit-selective GABA A receptor modulators AZD7325 and AZD6280 on plasma prolactin levels. Clin Pharm Drug Dev 2015; 4: 149-154.
43. Lee KK, Chan TY, Chan AW, Lau GS, Critchley JA: Use and abuse of benzodiazepines in Hong Kong 1990-1993-the impact of regulatory changes. J Toxicol Clin Toxicol 1995; 33: 597-602.
44. Dyer C: European court upholds UK ban on Halcion. BMJ 1999; 318: 418.
45. Leber P, Laughren T: The question of Halcion: overview and background for the 18 May 1992 PDAC Meeting. FDA Memo, 28 April 1992, pp 3-4.
46. CBHSQ: Drug Abuse Warning Network Methodology Report, 2011 Update. Rockville, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, 2013.
47. Turmel A, De Montigny C: Sensitization of rat forebrain neurons to serotonin by adinazolam, an antidepressant triazolobenzodiazepine. Eur J Pharmacol 1984; 99: 241-244.
48. Broderick PA: Alprazolam, diazepam, yohimbine, clonidine: in vivo CA1 hippocampal norepinephrine and serotonin release profiles under chloral hydrate anesthesia. Prog Neuropsychopharmacol Biol Psychiatry 1997; 21: 1117-1140.
49. Broderick PA, Hope O, Jeannot P: Mechanism of triazolo-benzodiazepine and benzodiazepine action in anxiety and depression: behavioral studies with concomitant in vivo CA1 hippocampal norepinephrine and serotonin release detection in the behaving animal. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 353-386.
50. Ashton CH: The benzodiazepines: what they do in the body (the Ashton manual). Benzodiazepines: how they work and how to withdraw. 2002. http://www. benzo. org. uk/manual/ bzcha01. htm (accessed May 28, 2013).
51. Teboul E, Chouinard G: A guide to benzodiazepine selection. I. Pharmacological aspects. Can J Psychiatry 1990; 35: 700-710.
52. Harward JL, Clinard VB, Jiroutek MR, Lingerfeldt BH, Muzyk AJ: Impact of a US Food and Drug Administration drug safety communication on zolpidem dosing: an observational retrospective cohort. Prim Care Companion CNS Disord 2015; 17: 94-98.
53. Brayfield A (ed): Martindale: The Complete Drug Reference, ed 38. London, Pharmaceutical Press, 2014.